NCI Grants Lysin Exclusive Rights to Mesothelin Cancer Immunotoxins
Published Date: 9/10/2025
Notice
Summary
The National Cancer Institute is planning to give Lysin Therapeutics an exclusive license to use their special anti-mesothelin immunotoxins to treat cancers that have mesothelin. This means Lysin can develop and sell new cancer treatments, potentially helping patients with tough-to-treat tumors. The deal could speed up new medicines and impact cancer care soon, with business and health benefits on the horizon.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
NCI plans exclusive license to Lysin
The National Cancer Institute (NCI) is contemplating granting an NCI Exclusive Patent License to Lysin Therapeutics, Inc., a company located in Silver Spring, MD, to practice inventions embodied in the patents listed in the notice's Supplementary Information. This gives Lysin the legal right to develop and commercialize the patented anti-mesothelin immunotoxin inventions listed in that supplement.
Potential new treatments for mesothelin cancers
The license under consideration covers anti-mesothelin immunotoxins for treating mesothelin-expressing cancers. If granted, the license would allow Lysin Therapeutics to develop and sell treatments that use these patented anti-mesothelin immunotoxins for cancers that express mesothelin.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11892 — Proposed Collection; 60-Day Comment Request; Specimen Resource Locator (National Cancer Institute)
The National Cancer Institute wants your thoughts on a new way to track and locate cancer research samples through their Specimen Resource Locator. This affects researchers and labs who use these samples, aiming to make finding and sharing easier without adding extra costs or delays. You’ve got 60 days to share your feedback and help shape this helpful tool!
2026-11390 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-11367 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for exciting science projects. If you’re involved in cell biology, heart disease, mental health, or cancer research, these reviews could impact your funding timeline and opportunities.
2026-11357 — National Library of Medicine; Notice of Partially Closed Meeting
The National Library of Medicine’s Board of Regents will hold a virtual meeting on July 16, 2026, with some parts open to the public and others closed to protect private info and trade secrets. This meeting affects researchers and grant applicants, as grant reviews will happen behind closed doors. Anyone can watch the open sessions online and send comments up to 15 days before the meeting—no registration needed!
2026-11018 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late June and early July 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which scientific projects get funding. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-10813 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Previous / Next Documents
Previous: 2025-17378 — Notice of Lodging of Proposed Second Material Modification to Consent Decree Under Title VI of the Clean Air Act
The Department of Justice is updating a deal with Trident Seafoods to fix problems with their old, leaky refrigeration systems that harm the ozone layer. They’re giving Trident four more years to meet one deadline but also making them upgrade one big fridge early and do extra leak checks. People have 30 days to share their thoughts on these changes before they’re final.
Next: 2025-17380 — Charter Amendments, Establishments, Reestablishments, Renewals, and Terminations; Novel and Exceptional Technology and Research Advisory Committee
The NIH is renewing the Novel and Exceptional Technology and Research Advisory Committee to keep advising on cool new biomedical tech. They’re holding a virtual meeting on September 29, 2025, to discuss public involvement in clinical research. This keeps important research moving forward with fresh ideas and public input, all without extra costs to taxpayers.